Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley analyst Michael Ulz maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 43.0
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Leerink Partners analyst Thomas Smith maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and sets the target price at $48.According to TipRanks data, the analyst has a success rate of 47.3%
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
SPS is a rare, progressive neurological autoimmune disorder causing debilitating muscle stiffness in the torso, arms and legs, thereby affecting the ability to walk or move.
Express News | HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) are experiencing notable momentum on the US stock charts today, following a pivotal regulatory approval. As of the latest pre-market check, KYTX stock has risen 8.78% to $10.78. RMAT Designation and Its Implications Kyverna Therapeutics (KYTX) reported that its KYV-101 has received Regenerative Medicine Advanced Therapy (RMAT) classification ...
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Bank of America Corporation (NYSE:BAC) to
Kyverna Therapeutics' KYV-101 Gains FDA Advanced Therapy Designation
Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced It Received FDA Regenerative Medicine Advanced Therapy Designation for KYV-101 in the Treatment of Patients With Refractory Stiff-person Syndrome
Express News | Kyverna's Kyv-101 Receives U.S. FDA Rmat Designation for Kyv-101 in the Treatment of Patients With Refractory Stiff-Person Syndrome
H.C. Wainwright Starts Kyverna at Neutral, Says Awaiting More Data
Kyverna Therapeutics Initiated at Neutral by HC Wainwright & Co.
Kyverna Therapeutics Initiated at Neutral by HC Wainwright & Co.
Kyverna Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/03/2024 -2.91% HC Wainwright & Co. → $8 Initiates Coverage On → Neutral 03/04/2024 373.3% JP Morgan → $
Express News | Kyverna Therapeutics, Inc : H.c. Wainwright Initiates Coverage With Neutral Rating and Target Price $8
Sector Update: Health Care Stocks Higher Late Afternoon
Health care stocks were higher late Thursday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 0.3%. The iShares Biotechnology ETF (IBB) rose
Kyverna Gains as FDA Clears Trial for Lead Therapy
Kyverna Therapeutics Gets FDA IND Clearance for KYV-101
By Chris Wack Kyverna Therapeutics said it has received clearance for its Investigational New Drug, or IND, application by the U.S. Food and Drug Administration for its T-cell product candidate, KYV-
Express News | Kyverna Therapeutics Shares Are Trading Higher After the Company Announced KYV-101 Received FDA IND Clearance for the Treatment of Patients With Treatment-refractory Stiff-Person Syndrome in the KYSA-8 Phase 2 Trial
Express News | Kyverna's Kyv-101 Receives U.S. FDA Ind Clearance for Treatment of Patients With Treatment-Refractory Stiff-Person Syndrome in the Kysa-8 Phase 2 Trial
Sector Update: Health Care Stocks Decrease Late Afternoon
Health care stocks were softer late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) edging down 0.1%. The iShares Biotechnology ETF (IBB)
Sector Update: Health Care
Health care stocks were softer late Friday afternoon, with the NYSE Health Care Index down 0.3% and the Health Care Select Sector SPDR Fund (XLV) edging down 0.1%. The iShares Biotechnology ETF (IBB)
No Data